Neurocrine Biosciences Inc (NBIX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Neurocrine Biosciences Inc (NBIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012213
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Neurocrine Biosciences Inc (Neurocrine) discovers, develops and commercializes pharmaceutical products for the treatment of neurologic, psychiatric and endocrine related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule is a US FDA approved selective vesicular monoamine transporter 2 inhibitor for the treatment of adults with tardive dyskinesia (TD). Its other major pipeline products include elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis and uterine fibroids and opicapone, a catechol-O-methyltransferase inhibitor (COMT inhibitor) intended for adult patients with Parkinson’s disease. It also develops drug candidates for the treatment of essential tremor and classic congenital adrenal hyperplasia. The company has development and licencing partnerships with AbbVie Inc, BIAL–Portela & CA, S.A. and Mitsubishi Tanabe Pharma. Neurocrine is headquartered in San Diego, California, the US.

Neurocrine Biosciences Inc (NBIX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Neurocrine Biosciences Enters into Licensing Agreement with Bial 10
Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 11
Equity Offering 12
Neurocrine Biosciences Raises USD288 Million in Public Offering of Shares 12
Neurocrine Biosciences Completes Public Offering Of Shares For US$142 Million 14
Neurocrine Biosciences Completes Over-allotment Option Of Underwritten Public Offering For US$88.5 Million 16
Debt Offering 18
Neurocrine Biosciences Raises USD517.5 Million in Private Placement of 2.25% Notes Due 2024 18
Neurocrine Biosciences Inc – Key Competitors 20
Neurocrine Biosciences Inc – Key Employees 21
Neurocrine Biosciences Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Nov 01, 2017: Neurocrine Biosciences Reports Third Quarter 2017 Results 23
Aug 03, 2017: Neurocrine Biosciences Reports Second Quarter 2017 Results 25
May 09, 2017: Neurocrine Biosciences Reports First Quarter 2017 Results 27
Feb 14, 2017: Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017 30
Nov 02, 2016: Neurocrine Biosciences Reports Third Quarter 2016 Results 33
Aug 03, 2016: Neurocrine Biosciences Reports Second Quarter 2016 Results 36
May 05, 2016: Neurocrine Biosciences Reports First Quarter 2016 Results 38
Feb 11, 2016: Neurocrine Biosciences Reports Year-End 2015 Results and Provides Investor Update for 2016 40
Corporate Communications 42
Nov 20, 2017: Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer 42
Jan 06, 2017: Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer 43
Dec 21, 2016: Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down 44
May 20, 2016: Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Neurocrine Biosciences Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Neurocrine Biosciences Enters into Licensing Agreement with Bial 10
Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 11
Neurocrine Biosciences Raises USD288 Million in Public Offering of Shares 12
Neurocrine Biosciences Completes Public Offering Of Shares For US$142 Million 14
Neurocrine Biosciences Completes Over-allotment Option Of Underwritten Public Offering For US$88.5 Million 16
Neurocrine Biosciences Raises USD517.5 Million in Private Placement of 2.25% Notes Due 2024 18
Neurocrine Biosciences Inc, Key Competitors 20
Neurocrine Biosciences Inc, Key Employees 21
Neurocrine Biosciences Inc, Subsidiaries 22

★海外企業調査レポート[Neurocrine Biosciences Inc (NBIX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • McCarthy Building Companies Inc:企業の戦略的SWOT分析
    McCarthy Building Companies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Mayne Pharma Group Ltd (MYX)-製薬・医療分野:企業M&A・提携分析
    Summary Mayne Pharma Group Ltd (Mayne Pharma), formerly Mayne Pharma International Pty Ltd, a subsidiary of Hospira Inc, is a specialty pharmaceutical company that manufactures and markets branded and generic medicinal products. The company’s products comprise astrix capsules and tablets, erymax cap …
  • Netsmart Technologies Inc-医療機器分野:企業M&A・提携分析
    Summary Netsmart Technologies Inc (Netsmart) is a subsidiary of GI Partner, is a provider of enterprise software solutions for health and human services providers and payers. It provides on-demand and on-premise software solutions to automate major financial, clinical and management processes to its …
  • Electricite de France SA:企業の戦略・SWOT・財務情報
    Electricite de France SA - Strategy, SWOT and Corporate Finance Report Summary Electricite de France SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Sakai Chemical Industry Co Ltd (4078):企業の財務・戦略的SWOT分析
    Sakai Chemical Industry Co Ltd (4078) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Kolorfusion International Inc:企業の戦略的SWOT分析
    Kolorfusion International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Agilent Technologies Inc (A)-製薬・医療分野:企業M&A・提携分析
    Summary Agilent Technologies Inc (Agilent) is a provider of instruments, reagents, software, services and consumables for comprehensive laboratory workflow. Its product portfolio comprises atomic absorption systems, bioanalyzers, gene expression microarrays and automation systems, among others. The …
  • Ingram Entertainment Inc.:企業の戦略・SWOT・財務情報
    Ingram Entertainment Inc. - Strategy, SWOT and Corporate Finance Report Summary Ingram Entertainment Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Aurora Spine Corp (ASG):企業の財務・戦略的SWOT分析
    Summary Aurora Spine Corp (Aurora) is a medical equipment provider that offers surgical tools. The company offers novel solutions in the spinal implant market through a range of minimally invasive, and regenerative spinal implant technologies. It develops and distributes spinal implant products whic …
  • Yakult Honsha Co Ltd (2267):企業の財務・戦略的SWOT分析
    Yakult Honsha Co Ltd (2267) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Vertex Pharmaceuticals Inc (VRTX):企業の財務・戦略的SWOT分析
    Vertex Pharmaceuticals Inc (VRTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Hon Hai Precision Industry Co Ltd (2317):企業の財務・戦略的SWOT分析
    Hon Hai Precision Industry Co Ltd (2317) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Pactiv LLC:企業の戦略・SWOT・財務情報
    Pactiv LLC - Strategy, SWOT and Corporate Finance Report Summary Pactiv LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Bluefish Pharmaceuticals AB-製薬・医療分野:企業M&A・提携分析
    Summary Bluefish Pharmaceuticals AB (Bluefish Pharmaceuticals) is a manufacturer and distributor of generic pharmaceutical products. The company provides products for various therapeutic areas including cardiovascular, the central nervous system, gastrointestinal, diabetes, oncology, dermatology, re …
  • Taisho Pharmaceutical Holdings Co Ltd:戦略・SWOT・企業財務分析
    Taisho Pharmaceutical Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Taisho Pharmaceutical Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Symbiomix Therapeutics LLC-製薬・医療分野:企業M&A・提携分析
    Summary Symbiomix Therapeutics LLC (Symbiomix) is a drug development company that offers development and commercialization of novel medicines. The company offers SYM-1219, for the treatment of several serious infections in women including bacterial vaginosis. Its SYM-1219 contains secnidazole, nitro …
  • Exillon Energy Plc (EXI):企業の財務・戦略的SWOT分析
    Summary Exillon Energy Plc (Exillon) is an oil exploration and production company. The company explores, produces and develops crude oil. Its services include drilling, exploration, appraisal, development, operations, management, and production services. Exillon’s operating assets are located in two …
  • Bossard Holding AG:企業の戦略・SWOT・財務情報
    Bossard Holding AG - Strategy, SWOT and Corporate Finance Report Summary Bossard Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Crexendo Inc (CXDO):企業の財務・戦略的SWOT分析
    Summary Crexendo Inc (Crexendo) is a technology company that offers critical voice and data technology infrastructure services. The company offers internet phones, colour internet phones, SIP phone, DTA phones and mobile applications. It offers cloud communication and network services. Crexendo’s ne …
  • Sanofi-Aventis Korea Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Sanofi-Aventis Korea Co Ltd (Sanofi-Aventis), a subsidiary of Sanofi is a developer, manufacturer and distributor of generic drugs and medical equipment. The company’s products include note vials lantus, lantus state solo star, she feeds the main vial la, feed her a solo star la shares, elro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆